Pharmacokinetic Comparisons of Two Donepezil Formulations

Overview

To compare the relative bioavailability and pharmacokinetic characteristics of a newly developed donepezil formulation with a conventional formulation in healthy subjects with a single dose, randomized, open-label, 2-sequence -2period crossover study.

Full Title of Study: “Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Donepezil Between Two Donepezil Products, Aricept® Tablet and Neuropezil ODT, in Healthy Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2008

Detailed Description

This single dose, open label, balanced, randomized, two-treatment, two-period, two-sequence, crossover study was conducted to compare the relative bioavailability and pharmacokinetic characteristics of a newly developed formulation with a conventional formulation in healthy subjects. For this, a single-center, randomized, single-dose, open-label, 2-way crossover study with a 21-day washout period was conducted in 22 healthy volunteers. Plasma samples for the analysis of donepezil were collected up to 240 h after drug administration. Participants received either reference or test drug formulation of 10 mg donepezil in the first period and the alternative formulation in the second period. Plasma concentrations of donepezil were determined by validated high-performance liquid chromatography coupled to tandem mass spectrometry detection. Pharmacokinetic parameters, including Cmax and AUC, were determined by noncompartmental analysis. Analysis of variance (ANOVA) was carried out using log-transformed Cmax and AUC, and the mean ratios and their 90% confidence intervals (CI) were calculated. According to regulatory requirements set forth by Korea and the US Food and Drug Administration, products meet the criteria for bioequivalence if the 90% CIs of the mean ratios for Cmax and AUC are within the range of 0.80 to 1.25.

Interventions

  • Drug: Donepezil, ODT 10 mg
    • Test- Donepezil Hydrochloride 10 mg Tablet single dose
  • Drug: Donepezil, 10 mg tablet
    • Reference: Donepezil Hydrochloride 10 mg Tablet

Arms, Groups and Cohorts

  • Active Comparator: Reference arm
    • Treated with Reference (Aricept, 10 mg donepezil tablet)
  • Experimental: Test arm
    • Treated with Test (Neuropezil, 10 donepezil ODT, orally disintegrating tablet)

Clinical Trial Outcome Measures

Primary Measures

  • donepezil pharmacokinetics: peak plasma concentrations (Cmax)
    • Time Frame: 240 hours
  • donepezil pharmacokinetics: Area under the time vs. plasma concentration curve from 0 to 240 hr(AUCall)
    • Time Frame: 240 hours
  • donepezil pharmacokinetics: Area under the time vs. plasma concentration curve from 0 to infinity(AUCinf)
    • Time Frame: 240 hours

Participating in This Clinical Trial

Inclusion Criteria

  • Males age 20 to 45 years – Body weight > 45 kg with +/- 20% of ideal body weight – Signed and dated informed consent form which meets all criteria of current FDA and KFDA regulations Exclusion Criteria:

  • subjects with acute conditions. – presence of history affecting ADME – Clinically significant history or current evidence of a hepatic, renal, gastrointestinal, or hematologic abnormality – Hepatitis B, hepatitis C, or HIV infection revealed on the laboratory findings – Any other acute or chronic disease – A history of hypersensitivity to donepezil – A history of alcohol or drug abuse – Participation in another clinical trial within 3 months – smoked >10 cigarettes daily – consumption over 5 glasses daily of beverages containing xanthine derivatives – use of any medication having the potential to affect the study results within 10 days before the start of the study.

Gender Eligibility: Male

Minimum Age: 20 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Korea University Anam Hospital
  • Collaborator
    • Chong Kun Dang Pharmaceutical Corp.
  • Provider of Information About this Clinical Study
    • Ji-Young Park, MD/Associate Professor of Clinical Pharmacology, Anam Hospital, Dept. of Clincial Pharmacology, Anam Hospital, Korea University College of Medicine, Seoul, Korea
  • Overall Official(s)
    • Ji-Young Park, MD, PhD, Principal Investigator, Anam Hospital, Korea Univeristy College of Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.